ArticleBritish journal of cancer2013

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.

A P Toner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.